Abstract
Cryptosporidium hominis is a protozoan parasite that causes acute gastrointestinal illness. There are no effective therapies for cryptosporidiosis, highlighting the need for new drug-lead discovery. An analysis of the protein-ligand interactions in two crystal structures of dihydrofolate reductase-thymidylate synthase (DHFR-TS) from C. hominis, determined at 2.8 and 2.87 A resolution, reveals that the interactions of residues Ile29, Thr58 and Cys113 in the active site of C. hominis DHFR provide a possible structural basis for the observed antifolate resistance. A comparison with the structure of human DHFR reveals active-site differences that may be exploited for the design of species-selective inhibitors.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Binding Sites
-
Cryptosporidium / enzymology*
-
Crystallization
-
Drug Resistance
-
Folic Acid Antagonists / pharmacology*
-
Ligands
-
Models, Molecular
-
Protein Structure, Secondary
-
Synchrotrons
-
Tetrahydrofolate Dehydrogenase / chemistry*
-
Tetrahydrofolate Dehydrogenase / genetics
-
Tetrahydrofolate Dehydrogenase / isolation & purification
-
Tetrahydrofolate Dehydrogenase / metabolism
-
Thymidylate Synthase / chemistry*
-
Thymidylate Synthase / genetics
-
Thymidylate Synthase / isolation & purification
-
Thymidylate Synthase / metabolism
-
X-Ray Diffraction
Substances
-
Folic Acid Antagonists
-
Ligands
-
Tetrahydrofolate Dehydrogenase
-
Thymidylate Synthase
Associated data
-
PDB/1QZF
-
PDB/1SEJ
-
PDB/R1QZFSF
-
PDB/R1SEJSF